MTPConnect is excited to announce the appointment of Andrew Bowskill to the team, in the role of Director of Stakeholder Engagement for Queensland.
Andrew joins us from Medicines Australia, where he was Manager of Industry and Regulatory Policy, engaging with a broad cross section of stakeholders including consumer groups, companies, peak bodies and Commonwealth and State officials. As well as his extensive networks, Andrew brings deep understanding of MTP industry and regulatory policy including R&D policy, intellectual property, trade agreements and biosimilars. Andrew has a Bachelor of Pharmacy from the University of Otago and has held a number of pharmacy roles in Queensland including Clinical Pharmacist, Adult Emergency and Medical Admissions and Planning Unit, Mater Pharmacy Services and Team Leader, Mater Private Hospital Pharmacy.
Andrew is working from MTPConnect’s new Queensland office, located at the Translational Research Institute (TRI) in Brisbane. A ‘bench to bedside’ medical research institute, the TRI is a collaboration between four major partners; University of Queensland Diamantina Institute and the UQ School of Medicine, QUT's Institute of Health and Biomedical Innovation, the Princess Alexandra Hospital Centres for Health research and Mater Research.
Through our Growth Centre Project Fund program, MTPConnect supports TRI and Vaxxas in an initiative to establish a flexible and accessible medtech/pharma clinical manufacturing facility to enable the translation of innovative, investigational products into clinical.
Listen to our podcast to hear how TRI and Vaxxas are enhancing MTP skills and manufacturing capabilities.